Teri Lawver joined Dexcom
(Nasdaq:DXCM)
as chief commercial officer just as the company got set for a massive commercial undertaking.
The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch of the G7.
A former Johnson & Johnson executive, Lawver became the first to serve in Dexcom’s newly created CCO role. As she assumed the position amid a crucial time for the company, she observed what makes Dexcom one of the leaders in the diabetes technology space — and potentially beyond.
“The first few months I’ve just reaffirmed the reasons that I joined Dexcom,” Lawver told Drug Delivery Business News. “It’s an unmatched opportunity for impact on human health, both at a micro level and a macro level, really distinctively, with a customer focus orientation to everything we do. And it’s a great team.”
Lawver spoke with DDBN on the heels of the American Diabetes Association’s 83rd Scientific Sessions. At that event, Dexcom revealed its plans for a new product launch by next year. She touched on the commercial effort there, as well as the launch of G7 and the company’s amended mission.
Get the full story at our sister site, Drug Delivery Business News.